Figure 1: Plasma osteopontin levels in newly diagnosed Alzheimer’s disease (AD) are elevated. The horizontal lines represent the mean values of each group, and asterisks show statistical significance ( ). (a) Osteopontin concentrations in plasma of 20 healthy control (HC), 20 aged-matched other noninflammatory neurologic diseases (OND), 18 clinically stable mild cognitive impairment patients (MCInc), 13 mild cognitive impairment converters (MCIc), 17 newly diagnosed AD (ADn), and 18 chronical AD patients (ADc) were determined using an enzyme-linked immunosorbent assay (ELISA). (b) The plasma osteopontin concentrations within the same individual ( ) at different disease statuses.